short communications
A mutation (G139A) in the MabA protein from Mycobacterium tuberculosis is reported that leads to complete protein inactivation and freezes the catalytic site into its closed form, even in the presence of the cofactor. This observation suggests a new way to develop anti-MabA drugs via protein stabilization of the `inactive' form.